Plus: A shift in bird flu strategy, a new vaccine for meningococcal disease, a new AI genomics model from Nvidia and more.

Purple Biotech (PPBT) is advancing into a Phase 2 study with NT219 in patients with recurrent/metastatic squamous cell carcinoma of the head ...

NT219, a novel agent designed to overcome tumor resistance to drug therapy, will be evaluated in combination with the standard-of-care head and ...

Leader in manufacturing reagents and critical components for biomedical research to leverage Etcembly’s AI platform to ...

The NIH says funding cuts would save it billions of dollars a year. D.C.-area industry and academic leaders say it would cripple R&D.

It has received multiple international approvals, including recognition from the Ministry of Health in Malaysia, a Non-Pesticide classification by the Malaysian Pesticide Board and is also approved by ...

Entrada Therapeutics' innovative Endosomal Escape Vehicle platform, poised to revolutionize drug delivery. Click here to read ...

Psilera, Inc. ("Psilera"), a biotechnology company developing groundbreaking therapies for hard-to-treat neurological ...

Clearside Biomedical, Inc. (NASDAQ:CLSD), currently valued at $81.15 million, is a biotechnology company focused on developing innovative therapies for blinding eye diseases using its proprietary SCS ...

The field of central nervous system (CNS) drug development is awash with activity. And major new centres of research are ...